Savara (SVRA) Other Operating Expenses (2010 - 2026)
Savara (SVRA) reported Other Operating Expenses of $24000.0 for Q1 2026, down 20.0% year-over-year from $30000.0 in Q1 2025, and up 318.18% on a QoQ basis from -$11000.0 in Q4 2025.
Savara (SVRA) has 17 years of Other Operating Expenses data on file, last reported at $24000.0 in Q1 2026.
- Quarterly Other Operating Expenses fell 20.0% year-over-year to $24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83000.0 (down 35.16% YoY) and the FY2025 annual result came in at $87000.0, down 33.08% from the prior year.
- Other Operating Expenses improved to $24000.0 in Q1 2026 per SVRA's latest filing, from -$11000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $36000.0 in Q3 2025 and bottomed at -$11000.0 in Q4 2025.
- The 5-year median for Other Operating Expenses is $30000.0 (2023), against an average of $20705.9.
- The widest annual swing landed in 2023, when Other Operating Expenses surged 357.14%; it then sank 134.38% in 2025.
- Tracing SVRA's Other Operating Expenses over 5 years: stood at $7000.0 in 2022, then soared by 357.14% to $32000.0 in 2023, then changed by 0.0% to $32000.0 in 2024, then slumped by 134.38% to -$11000.0 in 2025, then surged by 318.18% to $24000.0 in 2026.
- Per Business Quant, the three latest SVRA Other Operating Expenses figures stand at $24000.0 (Q1 2026), -$11000.0 (Q4 2025), and $36000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Sep 30, 2022 | 8,000.00 |
| Jun 30, 2022 | 8,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 47,000.00 |
| Mar 31, 2021 | 47,000.00 |
| Dec 31, 2020 | 66,000.00 |
| Sep 30, 2020 | 63,000.00 |
| Jun 30, 2020 | 68,000.00 |
| Mar 31, 2020 | 58,000.00 |
| Dec 31, 2019 | 19.49 Mn |
| Sep 30, 2019 | 56,000.00 |
| Jun 30, 2019 | 7.48 Mn |
| Mar 31, 2019 | 138,000.00 |
| Mar 31, 2018 | 21.69 Mn |
| Dec 31, 2017 | -2.21 Mn |
| Sep 30, 2017 | -111,000.00 |
| Jun 30, 2017 | -10.53 Mn |
| Mar 31, 2016 | 32,000.00 |
| Dec 31, 2015 | -99,000.00 |
| Sep 30, 2015 | 38,000.00 |
| Jun 30, 2015 | 37,000.00 |
| Mar 31, 2015 | 30,000.00 |
| Dec 31, 2014 | -7.26 Mn |
| Sep 30, 2014 | -7.86 Mn |
| Jun 30, 2014 | -7.00 Mn |
| Mar 31, 2014 | -7.52 Mn |
| Dec 31, 2013 | -2.02 Mn |
| Sep 30, 2013 | -6.92 Mn |
| Jun 30, 2013 | -6.44 Mn |
| Mar 31, 2013 | -9.07 Mn |
| Dec 31, 2012 | 117,587.00 |
| Sep 30, 2012 | -255,584.00 |
| Jun 30, 2012 | 242,638.00 |
| Mar 31, 2012 | -84,196.00 |
| Dec 31, 2011 | -1.12 Mn |
| Sep 30, 2011 | -479,338.00 |
| Jun 30, 2011 | 1.24 Mn |
| Mar 31, 2011 | 809,376.00 |
| Dec 31, 2010 | 333,664.00 |
| Sep 30, 2010 | 4,879.00 |
| Jun 30, 2010 | 5,767.00 |